NeOnc Technologies Holdings, Inc. Common Stock NTHI

NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

• GlobeNewswire Inc. 22 sept

  NeOnc’s Delivery may Finally Change the Equation for Brain Cancer’s Next Frontier

  NeOnc Technologies (NASDAQ: NTHI) is advancing NEO100, an intranasal-delivered therapy for IDH1-mutant gliomas, following promising Phase 2a results showing 48.9% six-month progression-free survival versus a 20% benchmark with no major toxicities. The company plans to seek FDA guidance on a registrational pathway, with potential broader implications for nose-to-brain drug delivery technology.

  

• GlobeNewswire Inc. 21 sept

  NeOnc Charting New Nasal Route to Treating Brain Cancer

  NeOnc Technologies (NASDAQ: NTHI) reported Phase 2a results for NEO100, an intranasal formulation of perillyl alcohol for recurrent high-grade glioma. The 24-patient study showed 48.9% six-month progression-free survival versus a 20% benchmark (p=0.0047), with median overall survival of 26.09 months. The novel nose-to-brain delivery approach aims to overcome blood-brain barrier challenges. While results are encouraging, the small sample size and open-label design warrant confirmation in larger randomized trials before regulatory approval.

  

• GlobeNewswire Inc. 16 sept

  NeOnc’s $629K Insider Buying Spree Follows Breakthrough Data and Now All Eyes Turn to the FDA

  NeOnc Technologies (NASDAQ: NTHI) executives have purchased approximately $629,000 in company shares following positive Phase 2a results for its brain-cancer therapy NEO100. The Phase 2a study met its primary endpoint with 48.9% six-month progression-free survival compared to a 20% benchmark, with a p-value of 0.0047. The company also announced a $15 million registered direct offering and has a second program, NEO212, advancing toward Phase 2 trials.

  

• GlobeNewswire Inc. 10 ago

  NeOnc Reports Second Quarter 2026 Financial Results and Confirms August 12 Topline Phase 2a NEO100 Data Readout

  NeOnc Technologies announced Q2 2026 financial results with increased R&D spending of $2.6M (up from $0.7M YoY) to support clinical development. The company completed topline analysis of its Phase 2a NEO100 study in recurrent IDH1-mutant high-grade glioma with results to be presented August 12, 2026. NeOnc secured UAE IND approvals for both NEO100 and NEO212 programs and appointed Nasim Shomali to its Board. The company reported a net loss of $14.2M for Q2 2026 with $2.0M in cash and an undrawn $10M credit line.